Skip to content
mapperlab
← Dashboard
Stock

AGIO

AGIOS PHARMACEUTICALS, INC.
Latest close $285 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
5
27 funds tracked
Ever held
7
Current + past
New this quarter
0
Exited this quarter
1

Marquee-fund ownership over time

Feb 16, 2021Feb 14, 2022May 15, 2025May 15, 2026
Now
5

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$45$28-37%
D.E. Shaw$45$28-37%
AQR Capital Management$45$28-37%
Millennium Management$45$28-37%
Two Sigma Investments re-entered$33$28-15%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Point72 Asset Management→ $28-35%
Maverick Capital 2× in & out→ $30-26%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at AGIOS PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
7
Filings · last 90d
16
Total on file
534
Recent SEC buffer
Most recent
Apr 6, 2026

30d / 90d windows measured from Apr 6, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 534 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · AGIOS PHARMACEUTICALS, INC.

Annual figures sourced directly from AGIOS PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$54.03M
FY2025+48% YoY
Net income
-$412.78M
FY2025-161% YoY
EPS (diluted)
$-7.12
FY2025-161% YoY
Free cash flow(?)
-$377.29M
FY2025+4% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for AGIOS PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ4 2025open$44$28-35%
Point72 Asset ManagementQ4 2025Q2 2026$44$28-35%
Two Sigma InvestmentsQ1 2025Q2 2025$33$28-15%
Citadel AdvisorsQ3 2024open$45$28-37%
D.E. ShawQ3 2024open$45$28-37%
AQR Capital ManagementQ3 2024open$45$28-37%
Millennium ManagementQ3 2024open$45$28-37%
Maverick CapitalQ4 2021Q1 2022$41$30-26%
Maverick CapitalQ1 2021Q3 2021$54$44-20%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.